Core Insights - The company, BoKang Vision, is a clinical-stage ophthalmic biotechnology firm focused on developing various therapies, with two core products: CBT-001 and CBT-009, both of which are self-developed [3] - CBT-001 targets the treatment of pterygium, a benign proliferative ocular surface disease, and has initiated Phase 3 multi-regional clinical trials in the US and China as of June 2022 and September 2023, respectively [3] - CBT-009 is aimed at treating myopia in adolescents aged 5 to 19, having completed Phase 1/2 clinical trials in January 2023, with plans to submit a new drug clinical trial application to the FDA by July 2024 [3] - Currently, there are no approved drugs for treating pterygium globally, and CBT-001 could become the first drug to treat this condition, potentially reducing the need for surgical removal [3] Product Development - The company has additional candidates in earlier stages of development, including two clinical-stage candidates (CBT-006 and CBT-004) and four preclinical candidates (CBT-007, CBT-199, CBT-145, and CBT-011) [3] - The pricing strategy for CBT-009 is being considered as an alternative treatment for myopia, with current surgical options being expensive and not suitable for patients under 18 [4] Financial Performance - The company has reported net losses during the historical performance period, with losses of approximately $67 million, $129 million, and $99 million for the years 2022, 2023, and 2024, respectively [4][5] - Revenue for 2024 is projected to be around $10 million, while the company continues to maintain a net debt position primarily due to the recognition of redeemable convertible preferred shares as liabilities [4] - Total assets decreased from $82 million in 2022 to $40 million in 2024, with total liabilities increasing from $227 million to $392 million during the same period [6]
眼科生物科技公司拨康视云通过港交所聆讯 三年累计亏损2.95亿美元
Zhi Tong Cai Jing·2025-06-22 01:07